An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...

A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be ...

Effect of a one-time sensitive screening intervention on prostate cancer mortality: The STHLM3 randomized trial.

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Networkfound that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...

Prostate-specific membrane antigen (PSMA)-PET is already a standard imaging tool in prostate cancer treatment. Now, a phase 3 clinical trial suggests the imaging modality may also help determine which ...

PSMA PET versus conventional imaging in metastatic prostate cancer: Evaluation of disease volume classification in a veteran cohort. Short-course (3-month) enzalutamide monotherapy in biochemically ...

The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...

A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first ...

Study findings further strengthen pivotal role of PSMA PET in the management of men with recurrence of prostate cancer after ...

Prostate cancer is one of the most common cancers worldwide and remains a significant cause of cancer-related death. With increasing life expectancy, its incidence is projected to rise steadily in the ...